Analyst: Roche May Drop Taspoglutide Diabetes Drug

IndyStar -- Roche Holding AG may drop development of the taspoglutide diabetes drug and return the rights to developer Ipsen SA because the treatment has too many side effects, Morgan Stanley analysts said.